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Addressing the overdiagnosis and overtreatment of breast cancer resulting from breast screening has 
been the focus of considerable media attention, and is consequently an international research 
priority.  Standard treatment involving surgery and adjuvant radiotherapy for small, biologically 
favourable screen detected cancers can be associated with significant complications with few 
potential benefits for patients.  Strategies to de-escalate components of the treatment pathway may 
address overtreatment and reduce morbidity for patients without detriment to their oncological 
outcomes.  This editorial discusses the design and rationale of the SMALL trial, a new study aiming to 
de-escalate surgical treatment and evaluate minimally invasive vacuum-assisted excision (VAE) as an 
alternative to standard surgery in in this setting. 
Addressing overtreatment within the NHSBSP 
Since the National Health Service Breast Screening Programme (NHSBSP) was established in 1988, 
there has been debate concerning the risks and benefits of mammographic screening. In 2010, the 
Nordic Cochrane Group fuelled controversy by suggesting that there was “no convincing evidence” 
that the NHSBSP saves lives [1].  The resulting UK Independent Panel Review of Breast Screening 
concluded that while the NHSBSP did result in a significant reduction in breast cancer mortality, there 
was undoubtedly overdiagnosis within the programme [2], and called for research to address this. The 
medical community has embraced this challenge; several trials to reduce overdiagnosis and resulting 
overtreatment have been designed focusing on de-escalating standard treatment to minimise harms.  
These include trials omitting breast surgery in patients with low risk ductal carcinoma in situ (the UK 
LORIS trial, EORTC LORD trial and US COMET trials), trials omitting axillary surgery in patients with 
radiologically normal axillary nodes and low risk breast cancers (the SOUND trial), and trials omitting 
radiotherapy in patients at low risk of recurrence (PRIMETIME) [3-5]. The SMALL trial aims to de-
escalate surgical treatment and evaluate minimally invasive vacuum-assisted excision as an alternative 
to standard surgery for small, biologically favourable, screen-detected breast cancers. 
Problems with current management strategies 
Screen-detected breast cancers are currently treated with surgical excision (usually image-guided 
wide local excision) and sentinel lymph node biopsy (SLNB) under general anaesthesia, followed by 
adjuvant therapies as agreed by the multidisciplinary team. Wide local excision may result in 
complications [6] and/or poor cosmetic outcomes[7] which may adversely impact on patient 
satisfaction and quality of life[8, 9]. In addition, up to 20% of patients may require additional surgery 
for re-excision of margins involved with tumour following histopathological assessment [10]. This has 
considerable impact on patient well-being and significant resource implications for the NHS [11] and 
although many international centres now accept the pathological definition of a clear margin as “no 
tumour at the inked resection margin” [12], current practice continues to vary across the UK [13] 
SLNB is currently standard of care for radiologically node negative patients, but the incidence of 
axillary nodal disease in this group is known to be low and ultrasound +/- biopsy have an extremely 
high negative predictive value [3]. Even in the context of a positive sentinel node, excellent regional 
control can be achieved in the axilla without further surgical dissection, suggesting that a low burden 
of nodal disease can be adequately controlled with adjuvant therapies [14]. Furthermore,  information 
on the extent of nodal involvement does not usually influence treatment selection[15], nor indeed 
alter long-term prognosis[16]. Data supporting the omission of axillary surgery in selected low-risk 
patients suggests that this approach is safe, with acceptable recurrence-free survival [17]. Taken 
together, these data suggest a lack of evidence to justify routine use of SLNB in this setting, given its 
attendant (albeit low) morbidity in terms of lymphoedema, numbness and paraesthesia [18]. 
A minimally invasive approach to treating small breast cancers 
Many of the small, biologically favourable cancers diagnosed by the NHSBSP are likely to represent 
overdiagnosis, and recent data suggests that such tumours have an excellent prognosis [19]. 
Treatment with conventional open surgery has been extrapolated from historical data, and there is 
no prospective evidence to support this approach. Minimally invasive techniques could therefore be 
developed for use in this setting, potentially reducing the morbidity and complications associated with 
standard treatment, allowing patients to avoid a general anaesthetic. These may also have significant 
benefits for the NHS, including cost savings associated with the avoidance of surgery. 
Vacuum-assisted biopsy (VAB) is one such minimally-invasive technique which is widely available in 
the UK. The VAB device is equipped with a large calibre needle, and the procedure is carried out under 
image-guidance (either ultrasound or X-ray guided) under local anaesthesia during a brief out-patient 
visit. Initially used for diagnostic purposes, VAB has evolved and is utilised as a tool for non-surgical 
excision of benign lesions[20, 21] as well as the management of lesions of uncertain malignant 
potential (B3 lesions)[22]. It is generally well-accepted by patients[23] and vacuum-assisted excision 
(VAE) is approved by National Institute for Health and Care Excellence (NICE) for excision of benign 
breast lesions.  Post-VAE imaging can accurately estimate complete removal of masses in 90% of cases 
[24]. There is therefore evidence to support repurposing of this technique for the excision of small 
screen-detected breast cancers with favourable biological characteristics. 
Study Design  
SMALL is a prospective, multi-centre, randomised (2:1) phase III trial of minimally invasive vacuum-
assisted excision versus surgery in patients with small, biologically favourable screen-detected breast 
cancer. It aims to generate high-quality, practice-changing clinical evidence to support the safe de-
escalation of surgical treatment within the context of standard adjuvant radiotherapy and endocrine 
therapy in selected patients. The study is designed to assess whether: 
• The extent of surgical treatment can be reduced in the context of standard adjuvant 
radiotherapy and endocrine therapy. 
• Vacuum-assisted excision is non-inferior to conventional surgery in terms of the requirement 
for a second operation to achieve complete resection of the cancer. 
• There is an acceptable local recurrence risk in the VAE arm with long-term follow up. 
 
The primary outcome measures in SMALL are re-excision rates and local recurrence-free survival time. 
The novel study design incorporates a randomised, non-inferiority comparison of the requirement for 
a second procedure between the techniques. Single arm follow-up of the VAE cohort will then allow 
determination of the local recurrence rate in this group. The trial schema is shown in Figure 1. 
Secondary outcomes will assess the psychological impact of VAE compared with standard surgery and 
health economics are included to determine the cost-effectiveness of the technique. SMALL requires 
recruitment of 800 patients over a four year recruitment period, with a subsequent follow up period 
of 5 years.  
Patients randomised to surgery will undergo standard surgical treatment (including SLNB and re-
excision of involved margins as deemed necessary by their local MDT), with adjuvant endocrine and 
radiotherapy according to local guidelines. Patients randomised to VAE will undergo the procedure 
under local anaesthetic, with insertion of marker clip and post-operative mammography to assess 
completeness of excision radiologically. SLNB will not be performed in the VAE arm of the study. 
Where excision is determined to be complete, patients will proceed to adjuvant radiotherapy and 
endocrine therapy (according to local protocols, which may include partial breast radiotherapy in 
keeping with NICE guidance). If residual disease is apparent on post-VAE imaging then patients will 
proceed to standard surgical treatment. 
In good prognosis cancers, the risk of local recurrence within the breast has been shown to be low 
following surgery and radiotherapy, with rates of around 1% at 5 years [24]. It is possible that this risk 
may be increased following VAE due to pathological incomplete resection. However, what is critical 
for long-term clinical outcomes is not the presence of low-volume microscopic disease, but rather its 
impact on local recurrence. It is important to recognize that following surgery, a clear resection margin 
does not mean that there is no residual tumour in the breast. Data suggests that even where additional 
surgery is not carried out to clear focally involved resection margins, acceptable local recurrence rates 
(<3%) at 5 years can be obtained with the use of adjuvant radiotherapy and endocrine therapy [25]. 
Therefore, in the VAE arm of SMALL, adjuvant radiotherapy and endocrine therapy are mandated to 
minimize the local recurrence risk. Furthermore, local recurrence rates will be closely monitored, and 
not be allowed to rise above a prespecified rate (3% per year). In this setting, local recurrence is a 
salvageable occurrence which can be managed by further surgery and does not impact on long-term 
survival. 
SMALL includes an internal pilot phase of 18 months to determine the acceptability and feasibility of 
recruitment. To address potential challenges to patient recruitment (such as identifying eligible 
patients, differences in levels of recruiters’ equipoise and patients’ preference for open surgery or 
VAE), SMALL will employ an integrated Quintet Recruitment Intervention (QRI) [25] aimed at 
optimising recruitment and informed consent. The QRI uses a novel qualitative and mixed methods 
approach pioneered during the HTA-funded ProtecT study and has been shown to support 
recruitment to time and target in other challenging randomised trials [26]. 
Conclusions 
The novel design of the SMALL trial provides a unique opportunity to evaluate the de-escalation of 
surgical treatment in screen-detected breast cancer, at a time when overtreatment remains a highly 
controversial issue. The introduction of VAE following a prospective randomised trial would represent 
a significant step forward in this setting, and it is anticipated that SMALL will pave the way for the 
development of future strategies for further treatment de-escalation. 
Acknowledgements  
The SMALL trial is funded by the National Institute for Health Research Health Technology Assessment 
Programme (project number 17/42/32). Shelley Potter is an NIHR Clinical Scientist (CS-2016-16-019) 
Disclaimer: The views and opinions expressed therein are those of the authors and do not necessarily 
reflect those of the Health Technology Assessment Programme, National Institute for Health 




1. Gotzsche, P. and K. Jorgensen, The breast screening programme and misinforming the 
public. Journal of the Royal Society of Medicine, 2011. 104(9): p. 361-369. 
2. Independent UK Panel on Breast Cancer Screening, The benefits and harms of breast cancer 
screening: an independent review. Lancet, 2012. 380(9855): p. 1778-86. 
3. Francis, A., L. Fallowfield, and D. Rea, The LORIS Trial: Addressing Overtreatment of Ductal 
Carcinoma In Situ. Clinical Oncology, 2015. 27: p. 6-8. 
4. Kirwan, C., et al., It’s PRIMETIME. Postoperative Avoidance of Radiotherapy: Biomarker 
Selection of Women at Very Low Risk of Local Recurrence. Clinical Oncology, 2016. 28: p. 
594-596. 
5. Gentilini, O. and U. Veronesi, Abandoning sentinel lymph node biopsy in early breast cancer? 
A new trial in progress at the European Institute of Oncology of Milan (SOUND: Sentinel node 
vs Observation after axillary UltraSouND). Breast, 2012. 21(5): p. 678-81. 
6. Losken, A., et al., A meta-analysis comparing breast conservation therapy alone to the 
oncoplastic technique. . Annals of Plastic Surgery, 2014. 72(2): p. 145-9. 
7. Clough, K., et al., Cosmetic sequelae after conservative treatment for breast cancer: 
classification and results of surgical correction. Annals of Plastic Surgery 1998. 41(5): p. 471-
81. 
8. Al-Ghazal, S., L. Fallowfield, and R. Blamey, Does cosmetic outcome from treatment of 
primary breast cancer influence psychosocial morbidity? European Journal of Surgical 
Oncology, 1999. 25(6): p. 571-3. 
9. Waljee, J., et al., Effect of esthetic outcome after breast-conserving surgery on psychosocial 
functioning and quality of life. Journal of Clinical Oncology 2008. 26: p. 3331-7. 
10. Public Health England and the Association of Breast Surgery, NHS Breast Screening 
Programme and Association of Breast Surgery: An audit of screen-detected breast cancers 
for the year April 2015 to March 2016. 2017. 
11. Grant, Y., et al., Patient-level costs in margin re-excision for breast-conserving surgery. 0(0). 
12. Moran, M., et al., Society of Surgical Oncology-American Society for Radiation Oncology 
consensus guideline on margins for breast-conserving surgery with whole-breast irradiation 
in stages I and II invasive breast cancer. Annals of Surgical Oncology, 2014. 21(3): p. 704-16. 
13. Tang, S.S.-K., et al., Current margin practice and effect on re-excision rates following the 
publication of the SSO-ASTRO consensus and ABS consensus guidelines: a national 
prospective study of 2858 women undergoing breast-conserving therapy in the UK and 
Ireland. European Journal of Cancer, 2017. 84: p. 315-324. 
14. Giuliano, A., et al., Locoregional recurrence after sentinel lymph node dissection with or 
without axillary dissection in patients with sentinel lymph node metastases: the American 
College of Surgeons Oncology Group Z0011 randomized trial. Annals of Surgery, 2010. 
252(3): p. 426-32. 
15. Straver, M., et al., Role of axillary clearance after a tumor-positive sentinel node in the 
administration of adjuvant therapy in early breast cancer. Journal of Clinical Oncology, 2010. 
28(5): p. 731-7. 
16. Giuliano, A., et al., Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall 
Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The 
ACOSOG Z0011 (Alliance) Randomized Clinical Trial. JAMA, 2017. 318(10): p. 918-26. 
17. O’Connell, R., et al., Long term results of treatment of breast cancer without axillary surgery 
– Predicting a SOUND approach? . European Journal of Surgical Oncology, 2016. 42(7): p. 
942-8. 
18. Purushotham, A., et al., Morbidity after sentinel lymph node biopsy in primary breast cancer: 
results from a randomized controlled trial. Journal of Clinical Oncology, 2005. 23(19): p. 
4312-21. 
19. Lannin, D. and S. Wang, Are Small Breast Cancers Good because They Are Small or Small 
because They Are Good? . The New England Journal of Medicine 2017. 376(23): p. 2286-91. 
20. Baez, E., et al., Minimal invasive complete excision of benign breast tumors using a three-
dimensional ultrasound-guided mammotome vacuum device. Ultrasound Obstet Gynecol, 
2003. 21(3): p. 267-72. 
21. Fine, R., et al., Percutaneous removal of benign breast masses using a vacuum-assisted hand-
held device with ultrasound guidance. Am J Surg, 2002. 184(4): p. 332-6. 
22. Strachan, C., et al., Outcome of a new patient pathway for managing B3 breast lesions by 
vacuum-assisted biopsy: time to change current UK practice? J Clin Pathol, 2016. 69(3): p. 
248-54. 
23. Eller, A., et al., Stereotactic vacuum-assisted breast biopsy (VABB)–a patients’ survey. 
Anticancer research, 2014. 34(7): p. 3831-7. 
24. Fine, R., et al., A prospective study of the removal rate of imaged breast lesions by an 11-
gauge vacuum-assisted biopsy probe system. Am J Surg 2001. 182(4): p. 335-40. 
25. Donovan, J.L., et al., Optimising recruitment and informed consent in randomised controlled 
trials: the development and implementation of the Quintet Recruitment Intervention (QRI). 
Trials, 2016. 17(1): p. 283. 
26. Rooshenas L., et al., The Quintet Recruitment Intervention supported five randomized trials 
to recruit to target: a mixed-methods evaluation. J Clin Epidemiol, 2018. 
 
  
Figure 1: SMALL trial schema 
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• <15mm maximum tumour diameter on mammogram
• No associated mammographic microcalcification
• Unifocal disease
• Grade 1 disease
• ER strongly positive (Allred ≥7 or equivalent)
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